Genprex Highlights Promising Preclinical Data for Diabetes Gene Therapy

Genprex ( (GNPX) ) has shared an update.

On April 28, 2026, Genprex announced that research collaborators will present new preclinical data on its diabetes gene therapy candidate GPX-002 at the American Society of Gene and Cell Therapy annual meeting in May 2026. The study in Type 2 diabetic mouse models found that pancreatic delivery of an AAV-encoded Pdx1/MafA construct reversed hyperglycemia, improved glucose-stimulated insulin secretion and shifted beta cells toward a more mature, functional state.

Mice on a high-fat diet that received the CMV- or beta-cell–targeted RIP versions of the therapy showed insulin secretion similar to healthy controls and a restoration of normal glycemic control four weeks after treatment. The findings, including increased mature insulin granules and complete rescue of diet-induced hyperglycemia after direct intrapancreatic infusion, underscore the potential for translating this gene therapy approach to humans via pancreatic delivery techniques, with implications for long-term management of Type 2 diabetes.

More about Genprex

Genprex, Inc. is a biotechnology company focused on developing gene therapy treatments, including candidates targeting diabetes and oncology. Its pipeline includes a diabetes gene therapy program aimed at improving or restoring pancreatic beta-cell function, with an emphasis on potential long-term glycemic control in Type 2 diabetes patients.

Average Trading Volume: 1,034,912

Technical Sentiment Signal: Sell

Current Market Cap: $9.39M

For a thorough assessment of GNPX stock, go to TipRanks’ Stock Analysis page.